KCT0002524
Active, not recruiting
未知
A single-blinded, split-face study for comparative evaluation on the efficacy and stability of the treatment of solar lentigo by picosecond Nd:YAG laser(Picocare 450) and traditional nanosecond Q-switched Nd:YAG laser(Pastelle)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- WONTECH
- Enrollment
- 49
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adults younger than 19 and younger than 74
- •2\. Those who have three or more photoreactive lentigo larger than 3 mm in diameter on the left and right sides of the face, respectively
- •3\. Persons who agreed to take a picture facial
- •4\. Persons who agree to and are willing to prohibit the use of topical / systemic steroids (Corticosteroids) or retinoids and topical / systemic skin whitening agents during the course of the trial
- •5\. Persons who agree to use the same skin care products in facial area during the clinical trial period and who are willing to comply with them
- •6\. I agree to use SPF 50 or more sunscreen every day on facial skin, avoiding excessive sunlight during the clinical trial period, and willingness to adhere to it
- •7\. Persons who agree not to undergo other aesthetic procedures, surgery or scarring operations on the face during the clinical trial period
- •8\. A woman who has been confirmed as negative in the pregnancy test and has agreed to be contraceptive during the trial period
- •9\. Those who voluntarily agree to participate in the clinical trial and are willing to comply with the clinical trial protocol
Exclusion Criteria
- •1\. A person with a history of paralysis due to light
- •2\. Those with facial infection, dermatitis, or rash
- •3\. Keloid scarring, hypertrophic scarring, Abnormal wound healing history.
- •4\. People with vitiligo, eczema, psoriasis
- •5\. A person with a history of connective tissue such as systemic lupus erythematosus (Lupus) or scleroderma (Scleroderma)
- •6\. Persons with a history of diseases that are stimulated by heat, such as herpes simplex and herpes zoster
- •7\. Those who have been receiving radiotherapy or have a history of chemotherapy
- •8\. A person with a malignant tumor in the face
- •9\. People with a history of allergic reactions to local anesthetics
- •10\. Persons who have used bleaching agents (Hydroquinone, Tranexamic acid, etc.), Isotretinoid (or Retinoid), light\-sensitive drugs and steroids within the last 6 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical Trial of Jelly Containing the Rare Sugar D-Alulose in Patients with Type 2 Diabetes MellitusType 2 diabetesD-alluloseMeSH Unique ID: D003924JPRN-jRCTs061230021Fukunaga Kensaku24
Active, not recruiting
Phase 1
A Randomized, Single-Blinded, Comparative Study of Mycosinate and Curanail in the Treatment of Fungal Nail InfectioOnychomycosisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-000294-78-IEektr Technologies60
Not yet recruiting
Phase 1
A comparative interventional study to assess the treatment modalities of atrophic acne scars such as fractional co2 laser and subcisioHealth Condition 1: L700- Acne vulgarisCTRI/2024/05/066623Belagavi institute of medical sciences
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002940-26-NLJanssen-Cilag International NV1,270
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerEUCTR2012-002940-26-SKJanssen-Cilag International NV1,270